Physician profile
David E Hipp
NPI 1396789152
$2,431.17
in general payments reported to CMS, 2019-2025
36 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.27 · 2020: $95.28 · 2021: $137 · 2022: $362 · 2023: $562 · 2024: $566 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $374.40 | 2021-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.25 | 2022-2025 | Jardiance |
| Pfizer INC. | $216.98 | 2019-2025 | |
| Amgen INC. | $156.01 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $124.58 | 2022-2023 | |
| Exact Sciences Corporation | $111.32 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $105.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $98.39 | 2024-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $93.19 | 2024-2025 | |
| Glaxosmithkline, LLC. | $69.36 | 2022-2025 | Shingrix, Arexvy |
| Radius Health, INC. | $61.82 | 2023-2025 | Tymlos |
| Lilly USA, LLC | $61.67 | 2023-2025 | Zepbound, Jardiance, Amyvid |
| Abiomed | $61.22 | 2024-2025 | Impella |
| Sumitomo Pharma America, INC. | $56.78 | 2023-2025 | Gemtesa |
| Pharmacosmos Therapeutics INC. | $50.42 | 2025 | Monoferric |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.